In vivo experiments also proved that anti-LGR5-mc-vc-PAB-MMAE significantly reduced tumor volume, and it eliminated CSCs, achieving complete remission (no tumor detected), without inducing toxicity to the normal portion of the intestinal tract [220]. The gene discussed is LGR5; the disease is neoplasm.